Investigation Report on China's Tocilizumab Market 2021-2025
|出版商||China Research and Intelligence||商品編碼||1008257|
|出版日期||內容資訊||英文 50 Pages
|中國的Tocilizumab市場(2021年∼2025年) Investigation Report on China's Tocilizumab Market 2021-2025|
|出版日期: 2021年05月28日||內容資訊: 英文 50 Pages||
Tocilizumab(銷售名:Actemra)，是Roche Pharma (Schweiz) AG 所開發的生物製藥，用於類風濕性關節炎(RA)的治療。 作為全身型幼年特發性關節炎(SJIA)的治療藥2016年首次在中國批準，2019年納入中國醫保。2020年，中國市場，Roche Pharma (Schweiz) AG 成為唯一的Tocilizumab的製藥企業。
The trade name of Tocilizumab is ACTEMRA, which was developed by Roche Pharma (Schweiz) AG. In 2013, its product was firstly approved in China and its indication is RA. Tocilizumab was approved in China as the first biological agent for the treatment of sJIA in 2016, was included in China's medical insurance in 2019, and was approved in China for the third indication of CRS in 2020. By 2020, Tocilizumab has registered a number of studies in China, and its indications include RA, sJIA, and CRS. By 2020, Roche Pharma (Schweiz) AG is the only manufacturer in the Chinese Tocilizumab market.
CRI's market research shows that the sales of Tocilizumab have had an increasing trend from 2016 to 2020. Since Tocilizumab was approved for the new indication sJIA in 2016, the sales increase in 2017 with 21.30% of the growth rate from 2016 to 2017. With the inclusion of Tocilizumab in China's medical insurance in 2019 and the approval of its new indications in China in 2020, the sales in 2020 increased evidently, from CNY20.07million in 2019 to CNY41.72 million in 2020. The growth rate is about 107.89%. The CAGR of Tocilizumab was 16.25% from 2016 to 2020.
According to CRI's market research, as the Tocilizumab market will expand from 2021 to 2025, its sales will continue to grow. The patent for the original tocilizumab injection has expired but no biosimilar drug has been approved in China. Currently, five pharmaceutical companies are carrying out relevant clinical trials. After Tocilizumab biosimilars are approved in the market, its manufacturers will gradually increase, the market will continue to grow and the price will decline. These situations will lead to an increase in Tocilizumab sales value and sales volume. In addition, Tocilizumab has been approved for 5 indications in other countries and China has approved 3 indications, so the number of approved indications in China has upside potential. It can be predicted that with the increase of indications, its sales will continue to grow with the expansion of the market in the future.